The board of directors of Allergan plc (NYSE:AGN) approved a dividend of USD0.72 per ordinary share for the Q4 2018, the company declared on Friday.
This cash dividend is due on 14 December 2018 to shareholders of record at the close of business as of 13 November 2018.
Headquartered in Dublin, Ireland, the pharmaceutical company is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
In addition, the company markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon